title: Altered stress induced by partial transection of the infraspinatus tendon leads to perlecan (HSPG2) accumulation in an ovine model of tendinopathy.
abstract: Perlecan is a widely distributed, heparan sulphate proteoglycan with roles in the sequestration of FGFs, PDGF, VEGF through which it promotes cell proliferation and matrix production. Perlecan also stabilises extracellular matrices through interaction with a diverse range of matrix components. This study examined the distribution of perlecan in an ovine partial transection tendinopathy model. In normal tendon, perlecan was immunolocalised to small blood vessels in intrafascicular regions in the tendon-bone and muscle-tendon attachments and to linear arrays of oval shaped tenocytes in the tendon mid-region. Partial transection in the mid-tendon region significantly increased perlecan accumulation within the fascicles, in granulation tissue filling the transection site and in the tendon-bone and tendon-muscle attachments. The accumulation of perlecan in the transected tendon and its known roles in matrix stabilisation and cell proliferation indicate possible roles in tendon remodelling and repair. Perlecan domain-1 has been used as a growth factor delivery vehicle for FGF-2, BMP-2 and BMP-7 in regenerative medicine but has yet to be evaluated in infraspinatus tendon repair. A better understanding of perlecan's contributions to pathobiological processes in remodelling tendon may be useful in such regenerative strategies in the future.
authors.affiliation: The Raymond Purves Bone and Joint Research Laboratories, Institute of Bone and Joint Research, Kolling Institute of Medical Research, University of Sydney, The Royal North Shore Hospital of Sydney, St. Leonards, NSW 2065, Australia. james.melrose@sydney.edu.au
authors.forename: James
authors.initials: J
authors.lastname: Melrose
authors.forename: Margaret M
authors.initials: MM
authors.lastname: Smith
authors.forename: Susan M
authors.initials: SM
authors.lastname: Smith
authors.forename: Varshini
authors.initials: V
authors.lastname: Ravi
authors.forename: Allan A
authors.initials: AA
authors.lastname: Young
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Dart
authors.forename: David H
authors.initials: DH
authors.lastname: Sonnabend
authors.forename: Christopher B
authors.initials: CB
authors.lastname: Little
mesh_terms: D000818:Animals; D049109:Cell Proliferation; D004195:Disease Models, Animal; D005109:Extracellular Matrix / Q000378:metabolism; D016222:Fibroblast Growth Factor 2 / Q000378:metabolism; D019812:Heparan Sulfate Proteoglycans / Q000378:metabolism*; D006801:Humans; D010982:Platelet-Derived Growth Factor / Q000378:metabolism; D044968:Regenerative Medicine; D017006:Rotator Cuff / Q000098:blood supply / Q000378:metabolism / Q000473:pathology; D034561:Sheep, Domestic / Q000378:metabolism* / Q000502:physiology; D052256:Tendinopathy / Q000378:metabolism* / Q000473:pathology; D013710:Tendons / Q000098:blood supply / Q000254:growth & development / Q000378:metabolism*; D042442:Vascular Endothelial Growth Factors / Q000378:metabolism; D014945:Wound Healing / Q000502:physiology
chemical_list: D019812:Heparan Sulfate Proteoglycans; D010982:Platelet-Derived Growth Factor; D042442:Vascular Endothelial Growth Factors; D016222:Fibroblast Growth Factor 2; C071927:perlecan